Functional analysis of ryanodine receptor type 1 p.R2508C mutation in exon 47.
OBJECTIVE
Malignant hyperthermia (MH) is a pharmacogenetic disorder of intracellular calcium homeostasis with an autosomal dominant inheritance. Most of the reported mutations in exon 47 were identified in Asian patients. However, no functional analysis of p.R2508C has been performed. We therefore conducted a functional analysis of the mutation by altering calcium homeostasis in human embryonic kidney (HEK) 293 cells transfected with the p.R2508C mutation in exon 47 of the ryanodine receptor 1 (RYR1).


METHODS
The entire RYR1 coding region from genomic DNA, which was extracted from the biopsied muscle specimens of two patients, was sequenced. The p.R2508C mutation was introduced into rabbit RYR1 cDNA, and wild-type or p.R2508C mutant cDNAs were transfected into HEK-293 cells. Using the calcium-sensitive probe Fura 2, we utilized the 340/380 nm ratio to analyze alterations in calcium homeostasis following treatment with caffeine and 4-chloro-m-cresol (4CmC).


RESULTS
Genetic analysis revealed a C-->T point mutation of RYR1 exon 47 at position 7522, resulting in an amino acid exchange of arginine for cysteine at amino acid 2508. The half-maximal activation concentrations (EC(50)) of caffeine and 4CmC for HEK-293 cells transfected with the p.R2508C mutation were 1.86 +/- 0.23 mM and 73.14 +/- 19.44 microM, while those for wild-type RYR1 were 2.62 +/- 0.23 mM and 179.31 +/- 35.23 microM, respectively.


CONCLUSIONS
We demonstrated that the transfected RYR1 mutant was more sensitive to caffeine and 4CmC than wildtype RYR1. These findings suggest that the p.R2508C mutation may be pathogenetic for susceptibility to MH.
Migita
Takako
T
Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
Mukaida
Keiko
K
Hamada
Hiroshi
H
Yasuda
Toshimichi
T
Haraki
Toshiaki
T
Nishino
Ichizo
I
Murakami
Nobuyuki
N
Kawamoto
Masashi
M
D000293:Adolescent; D000768:Anesthesia, General; D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002460:Cell Line; D004247:DNA / Q000235:genetics; D018076:DNA, Complementary / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D005091:Exons / Q000235:genetics*; D005260:Female; D006801:Humans; D008305:Malignant Hyperthermia / Q000235:genetics*; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000473:pathology; D016296:Mutagenesis; D009154:Mutation / Q000235:genetics* / Q000502:physiology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011817:Rabbits; D019837:Ryanodine Receptor Calcium Release Channel / Q000235:genetics* / Q000502:physiology*; D012600:Scoliosis / Q000601:surgery; D013050:Spectrometry, Fluorescence; D014162:Transfection
D018076:DNA, Complementary; D010726:Phosphodiesterase Inhibitors; D019837:Ryanodine Receptor Calcium Release Channel; D002110:Caffeine; D004247:DNA; D002118:Calcium
Hum Mutat. 2005 Nov;26(5):413-25
16163667
Anesthesiology. 2006 Jun;104(6):1146-54
16732084
Anesth Analg. 2004 Jul;99(1):103-107
15281512
Clin Genet. 2002 Aug;62(2):135-46
12220451
J Biol Chem. 1997 Oct 17;272(42):26332-9
9334205
Pharmacogenomics. 2008 Nov;9(11):1657-72
19018722
Hum Mol Genet. 2000 Nov 1;9(18):2599-608
11063719
Anesthesiology. 2008 Sep;109(3):457-64
18719443
Br J Anaesth. 2001 Feb;86(2):283-7
11573677
Methods Enzymol. 1988;157:12-26
3231088
Cell Calcium. 2003 Aug;34(2):163-8
12810058
Anesthesiology. 2005 Mar;102(3):515-21
15731587
Brain. 2006 Jun;129(Pt 6):1470-80
16621918
Hum Mutat. 2006 Oct;27(10):977-89
16917943
J Anesth. 2007;21(2):285-8
17458663
J Biol Chem. 1999 Jan 8;274(2):693-702
9873004
J Anesth. 2000 Jan 20;14(1):6-13
14564603